TABLE OF CONTENTS
1 INTRODUCTION 36
1.1 OBJECTIVES OF THE STUDY 36
1.2 MARKET DEFINITION 36
1.3 OVERVIEW OF THE GLOBAL TUMOR ABLATION MARKET 36
1.4 CURRENCY AND PRICING 38
1.5 LIMITATIONS 38
1.6 MARKETS COVERED 38
2 MARKET SEGMENTATION 41
2.1 MARKETS COVERED 41
2.2 GEOGRAPHICAL SCOPE 42
2.3 YEARS CONSIDERED FOR THE STUDY 43
2.4 DBMR TRIPOD DATA VALIDATION MODEL 44
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 47
2.6 MULTIVARIATE MODELLING 48
2.7 TYPE SEGMENT LIFELINE CURVE 49
2.8 MARKET END USERS COVERAGE GRID 50
2.9 DBMR MARKET POSITION GRID 51
2.10 VENDOR SHARE ANALYSIS 52
2.11 SECONDARY SOURCES 53
2.12 ASSUMPTIONS 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 56
4.1 PESTEL ANALYSIS 59
4.2 PORTER’S FIVE FORCES MODEL 60
5 REGULATORY FRAMEWORK 61
5.1 REGULATORY SCENARIO IN THE U.S 61
5.2 REGULATORY SCENARIO IN GERMANY 62
5.3 REGULATORY SCENARIO IN CHINA 62
5.4 REGULATORY SCENARIO IN AUSTRALIA 63
5.5 REGULATORY SCENARIO IN BRAZIL 63
5.6 REGULATORY SCENARIO IN SAUDI ARABIA 64
6 MARKET OVERVIEW 65
6.1 DRIVERS 67
6.1.1 RISING PREVALENCE OF CANCER GLOBALLY 67
6.1.2 INCREASING INCLINATION OF SURGEONS AND PATIENTS TOWARD MINIMALLY INVASIVE PROCEDURES 67
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS 68
6.1.4 INCREASING AWARENESS AND EDUCATION 68
6.2 RESTRAINTS 69
6.2.1 REGULATORY HURDLES FOR APPROVAL 69
6.2.2 LIMITED CLINICAL EVIDENCE 69
6.3 OPPORTUNITIES 70
6.3.1 FAVORABLE REIMBURSEMENT SCENARIO 70
6.3.2 STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 70
6.4 CHALLENGES 71
6.4.1 TECHNICAL CHALLENGES IN TARGETING THE TUMOR 71
6.4.2 COMPETITION FROM ALTERNATIVE TREATMENT MODALITIES 71
7 GLOBAL TUMOR ABLATION MARKET, BY TYPE 72
7.1 OVERVIEW 73
7.2 THERMAL ABLATION 76
7.2.1 TUMOR ABLATION SYSTEMS 77
7.2.1.1 RADIOFREQUENCY 78
7.2.1.1.1 BIPOLAR 78
7.2.1.1.2 MULTIPOLAR 78
7.2.2 IMAGE GUIDANCE PRODUCTS AND ACCESSORIES 78
7.2.2.1 CT 79
7.2.2.2 MR IMAGING 79
7.2.2.3 FLUOROSCOPY 79
7.2.2.4 OTHERS 79
7.2.2.5 MICROWAVE 79
7.2.2.6 CRYOABLATION 79
7.2.2.7 HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) 79
7.2.2.8 LASER 79
7.3 CHEMICAL ABLATION 79
7.3.1 ETHANOL 80
7.3.2 ACETIC ACID 80
8 GLOBAL TUMOR ABLATION MARKET, BY TYPES OF TREATMENT 81
8.1 OVERVIEW 82
8.2 PERCUTANEOUS 85
8.2.1 BREAST CANCER 86
8.2.2 LUNG CANCER 86
8.2.3 PROSTATE CANCER 86
8.2.4 LIVER CANCER 86
8.2.5 KIDNEY CANCER 86
8.2.6 OTHER CANCERS 86
8.3 LAPAROSCOPY 86
8.3.1 BREAST CANCER 87
8.3.2 LUNG CANCER 87
8.3.3 PROSTATE CANCER 87
8.3.4 LIVER CANCER 87
8.3.5 KIDNEY CANCER 88
8.3.6 OTHER CANCERS 88
8.4 SURGICAL 88
8.4.1 BREAST CANCER 89
8.4.2 LUNG CANCER 89
8.4.3 PROSTATE CANCER 89
8.4.4 LIVER CANCER 89
8.4.5 KIDNEY CANCER 89
8.4.6 OTHER CANCERS 89
9 GLOBAL TUMOR ABLATION MARKET, BY CANCER TYPE 90
9.1 OVERVIEW 91
9.2 BREAST CANCER 94
9.3 LUNG CANCER 94
9.4 PROSTATE CANCER 95
9.5 LIVER CANCER 96
9.6 KIDNEY CANCER 97
9.7 BONE CANCER 98
9.8 OTHERS 99
10 GLOBAL TUMOR ABLATION MARKET, BY END USERS 100
10.1 OVERVIEW 101
10.2 HOSPITALS 104
10.3 ONCOLOGY CENTERS 104
10.4 OTHERS 105
11 GLOBAL TUMOR ABLATION MARKET, BY DISTRIBUTION CHANNEL 106
11.1 OVERVIEW 107
11.2 DIRECT TENDER 110
11.3 RETAIL SALES 110
12 GLOBAL TUMOR ABLATION MARKET, BY REGION 112
12.1 OVERVIEW 113
12.2 NORTH AMERICA 118
12.2.1 U.S. 127
12.2.2 CANADA 132
12.2.3 MEXICO 137
12.3 EUROPE 142
12.3.1 GERMANY 152
12.3.2 U.K. 157
12.3.3 FRANCE 162
12.3.4 ITALY 167
12.3.5 RUSSIA 172
12.3.6 SPAIN 177
12.3.7 NETHERLANDS 182
12.3.8 SWITZERLAND 187
12.3.9 BELGIUM 192
12.3.10 TURKEY 197
12.3.11 REST OF EUROPE 202
12.4 ASIA PACIFIC 203
12.4.1 CHINA 213
12.4.2 JAPAN 218
12.4.3 INDIA 223
12.4.4 AUSTRALIA 228
12.4.5 SOUTH KOREA 233
12.4.6 INDONESIA 238
12.4.7 PHILIPPINES 243
12.4.8 THAILAND 248
12.4.9 MALAYSIA 253
12.4.10 SINGAPORE 258
12.4.11 REST OF ASIA-PACIFIC 263
12.5 SOUTH AMERICA 264
12.5.1 BRAZIL 273
12.5.2 ARGENTINA 278
12.5.3 REST OF SOUTH AMERICA 283
12.6 MIDDLE EAST AND AFRICA 284
12.6.1 SAUDI ARABIA 293
12.6.2 SOUTH AFRICA 298
12.6.3 U.A.E. 303
12.6.4 EGYPT 308
12.6.5 ISRAEL 313
12.6.6 REST OF MIDDLE EAST AND AFRICA 318
13 GLOBAL TUMOR ABLATION MARKET, COMPANY LANDSCAPE 319
13.1 COMPANY SHARE ANALYSIS: GLOBAL 319
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 320
13.3 COMPANY SHARE ANALYSIS: EUROPE 321
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 322
14 SWOT ANALYSIS 323
15 COMPANY PROFILE 324
15.1 BOSTON SCIENTIFIC CORPORATION 324
15.1.1 COMPANY SNAPSHOT 324
15.1.2 REVENUE ANALYSIS 324
15.1.3 COMPANY SHARE ANALYSIS 325
15.1.4 PRODUCT PORTFOLIO 325
15.1.5 RECENT DEVELOPMENT 325
15.2 MEDTRONIC 326
15.2.1 COMPANY SNAPSHOT 326
15.2.2 REVENUE ANALYSIS 326
15.2.3 COMPANY SHARE ANALYSIS 327
15.2.4 PRODUCT PORTFOLIO 327
15.2.5 RECENT DEVELOPMENT 327
15.3 OLYMPUS 328
15.3.1 COMPANY SNAPSHOT 328
15.3.2 REVENUE ANALYSIS 328
15.3.3 COMPANY SHARE ANALYSIS 329
15.3.4 PRODUCT PORTFOLIO 329
15.3.5 RECENT DEVELOPMENT 329
15.4 STRYKER 330
15.4.1 COMPANY SNAPSHOT 330
15.4.2 REVENUE ANALYSIS 330
15.4.3 COMPANY SHARE ANALYSIS 331
15.4.4 PRODUCT PORTFOLIO 331
15.4.5 RECENT DEVELOPMENT 331
15.5 BIOTRONIK 332
15.5.1 COMPANY SNAPSHOT 332
15.5.2 COMPANY SHARE ANALYSIS 332
15.5.3 PRODUCT PORTFOLIO 333
15.5.4 RECENT DEVELOPMENT 333
15.6 ANGIODYNAMICS. 334
15.6.1 COMPANY SNAPSHOT 334
15.6.2 REVENUE ANALYSIS 334
15.6.3 PRODUCT PORTFOLIO 335
15.6.4 RECENT DEVELOPMENT 335
15.7 BIOVENTUS LLC. 336
15.7.1 COMPANY SNAPSHOT 336
15.7.2 PRODUCT PORTFOLIO 336
15.7.3 RECENT DEVELOPMENT 336
15.8 BVM MEDICAL LIMITED 337
15.8.1 COMPANY SNAPSHOT 337
15.8.2 PRODUCT PORTFOLIO 337
15.8.3 RECENT DEVELOPMENT 337
15.9 EDAP TMS 338
15.9.1 COMPANY SNAPSHOT 338
15.9.2 REVENUE ANALYSIS 338
15.9.3 PRODUCT PORTFOLIO 339
15.9.4 RECENT DEVELOPMENT 339
15.10 ETHICON, INC. 340
15.10.1 COMPANY SNAPSHOT 340
15.10.2 PRODUCT PORTFOLIO 340
15.10.3 RECENT DEVELOPMENT 340
15.11 HEALTHTRONICS, INC. 341
15.11.1 COMPANY SNAPSHOT 341
15.11.2 PRODUCT PORTFOLIO 341
15.11.3 RECENT DEVELOPMENT 341
15.12 ICECURE MEDICAL 342
15.12.1 COMPANY SNAPSHOT 342
15.12.2 REVENUE ANALYSIS 342
15.12.3 PRODUCT PORTFOLIO 343
15.12.4 RECENT DEVELOPMENT 343
15.13 INSIGHTEC. 344
15.13.1 COMPANY SNAPSHOT 344
15.13.2 PRODUCT PORTFOLIO 344
15.13.3 RECENT DEVELOPMENT 344
15.14 INTEGRA LIFESCIENCES 345
15.14.1 COMPANY SNAPSHOT 345
15.14.2 REVENUE ANALYSIS 345
15.14.3 PRODUCT PORTFOLIO 346
15.14.4 RECENT DEVELOPMENT 346
15.15 MERIT MEDICAL SYSTEMS. 347
15.15.1 COMPANY SNAPSHOT 347
15.15.2 REVENUE ANALYSIS 347
15.15.3 PRODUCT PORTFOLIO 348
15.15.4 RECENT DEVELOPMENT 348
15.16 SONABLATE CORP. 349
15.16.1 COMPANY SNAPSHOT 349
15.16.2 PRODUCT PORTFOLIO 349
15.16.3 RECENT DEVELOPMENT 349
15.17 TERUMO EUROPE NV 350
15.17.1 COMPANY SNAPSHOT 350
15.17.2 PRODUCT PORTFOLIO 350
15.17.3 RECENT DEVELOPMENT 350
16 QUESTIONNAIRE 351
17 RELATED REPORTS 354
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
